Warner Chilcott Limited announced today that LEO Pharma A/S ("LEO Pharma") has received a Right of Appeal Notice from the U.S. Patent and Trademark Office (the "USPTO"). In September 2006, the USPTO ordered a reexamination of LEO Pharma's US Patent No. 6,753,013 (the "013 Patent") in response to a request made by Galderma R&D. The 013 Patent covers TACLONEX(R) products and certain of LEO Pharma's products in development. Warner Chilcott markets and sells TACLONEX(R) products in the United States under a license agreement with LEO Pharma and has license rights to certain products in development.
The details can be read here.
No comments:
Post a Comment